Companies › Amivas
1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease, Oncology; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Artesunate Antimalarial artemisinin derivative with antiviral properties against CMV | – | Phase 2 | CMV Infection; Chronic Myeloid Leukemia (CML) | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07022743 | Artesunate | Phase 2 | Chronic Myeloid Leukemia (CML) | Oncology | Jun 2027 |
| NCT06853184 | Artesunate | Phase 2 | CMV Infection | Infectious disease | May 2028 |
No annotated target.
–
Tetraphase Pharmaceuticals Cantex Pharmaceuticals The Skin Center Dermatology Group NanoEcho Syncromune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.